Skip to main content
letter
. 2023 Jun 13;37(7):1583–1587. doi: 10.1038/s41375-023-01937-6

Fig. 1. AML xenografts are susceptible to transient LNP/miR-193b treatment in vitro.

Fig. 1

A The absolute number of human AML PDX cells after treatment with single dose of 4 µg/ml LNPs. B Percentage of apoptotic cells (Annexin V+) on day 2 post treatment. A, B Data are represented as the mean ± standard deviation of three independent biological replicates (two-way ANOVA). C Absolute number of CFUs in methylcellulose-based colony-forming assays of LNPs-treated AML PDXs. Data are shown as the mean ± standard deviation of four plates from two biological replicates (two-way ANOVA).